Research programme: signal transduction pathway inhibitors - Amgen/U3 Pharma
Alternative Names: U3-1800Latest Information Update: 22 Mar 2010
At a glance
- Originator Amgen; U3 Pharma
- Class Antibodies
- Mechanism of Action Receptor protein-tyrosine kinase antagonists; Signal transduction pathway inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 26 May 2008 U3 Pharma has been acquired by Daiichi Sankyo Company
- 17 Apr 2008 This programme is still in active development
- 03 Apr 2006 Abgenix has been acquired and merged into Amgen